Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation

Autor: Heim, Catrin, Hartig, Leonie, Weinelt, Nadine, Moser, Laura M., Salzmann-Manrique, Emilia, Merker, Michael, Wels, Winfried S., Tonn, Torsten, Bader, Peter, Klusmann, Jan-Henning, van Wijk, Sjoerd J.L., Rettinger, Eva
Zdroj: In Molecular Therapy: Oncology 20 June 2024 32(2)
Databáze: ScienceDirect